MBS Digest
Metabolic & Bariatric Surgery
EDITORIAL
Editor’s note: This editorial was submitted by Dr. Samer G. Mattar, Section A Editor, MBS Digest. — MBS Editors
What Are the Prospects for a Vaccine Against Obesity?
By Samer G. Mattar, MD, FACS, FASMBS, DABOM
The past few years have delivered medical breakthroughs that would have been unimaginable in earlier eras. Among the most astonishing has been the emergence of highly effective incretin-based therapies that can reverse the ravages of obesity and its associated metabolic syndrome. I recall the great Walter Pories once describing this possibility as a distant “moonshot,” an almost fantastical idea. Yet here we are, witnessing an explosion of innovation in a field long neglected, if not outright marginalized, by all but a dedicated few.
As our patients reap the benefits of these therapies, attention naturally turns to what lies ahead. More potent incretin agents are already in development, promising greater efficacy and improved safety profiles. Still, like all medications, their benefits persist only while they are taken. Real-world data show that 50–65% of patients discontinue GLP-1 therapy within the first year, and most experience 60–75% weight recurrence, a compelling reminder of the enduring superiority of metabolic bariatric surgery in achieving durable weight control.
This raises a provocative question: What if a class of therapeutics could produce lasting—perhaps even permanent—protection against obesity?
Recent advances in RNA technology have transformed the landscape of immunology and oncology, enabling vaccines that treat cancers and immune-mediated diseases with unprecedented success. Could similar strategies be applied to obesity?
Emerging research highlights the central roles of microRNAs, long noncoding RNAs, circular RNAs, and tRNA-derived small RNAs in regulating adipogenesis, insulin signaling, and appetite control. These discoveries raise the tantalizing possibility of RNA-based vaccines that modulate metabolic pathways and confer long-term resistance to weight gain.
The conceptual appeal is obvious. A vaccine, or a combination of vaccines, that delivers durable protection against this chronic, relapsing disease would be transformative. Potential immunologic targets include ghrelin, GIP, somatostatin, and various adipose-tissue antigens. Active immunization against endogenous orexigenic or metabolic signals could, in theory, provide sustained benefit without continuous dosing.
Yet the scientific reality remains sobering. All these targets have been evaluated only in preclinical animal models, primarily mice and rodents. While many studies demonstrate meaningful changes in food intake, the effects on body weight have been modest and transient. Safety concerns loom large: immunizing against endogenous molecules risks provoking irreversible autoimmune reactions. Additional practical challenges include selecting the optimal vaccine platform, determining the route of administration, and establishing schedules for initial and booster dosing.
On balance, lifelong immunity to obesity remains a distant glimmer, being scientifically plausible but far from realization. Still, the trajectory of innovation in metabolic medicine suggests that no frontier is permanently out of reach. If recent history teaches us anything, it is that human ingenuity transforms the improbable into the attainable.
THE BOTTOM LINE
“On balance, lifelong immunity to obesity remains a distant glimmer, being scientifically plausible but far from realization. Still, the trajectory of innovation in metabolic medicine suggests that no frontier is permanently out of reach.”
Disclosures. Dr. Mattar’s financial and professional relationships are listed in the MBS Digest Disclosure Registry. Entries are self-reported and shown as submitted. The views expressed in this editorial are the author’s own and do not necessarily represent the position of the MBS Digest Editorial Board.
Dr. Mattar is Professor of Surgery and Chief of the Section of Metabolic and Bariatric Surgery at Baylor College of Medicine. He is a former President of the American Society for Metabolic and Bariatric Surgery and the current President of the North American Chapter of the International Federation for the Surgery and Other Therapies for Obesity (IFSO).
Stop typing what you could say in 10 seconds.
Wispr Flow turns your voice into clean, professional text inside any app. Emails, Slack, client updates — speak once, send without editing. 4x faster than typing.
Production Editor: John D. Scott, MD, FACS | [email protected]
We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected].
The MBS Digest | For Educational Purposes Only